Entrada Therapeutics, Inc. TRDA
4.72 USD -0.39 (-7.63%)
At closeNov 3, 2026, 4:01 PM EST
4.72 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
4.62 Day range 5.08
4.11 52-week range 16.45
- YTD
- -54.09%
- 1 year
- -30.38%
Analyst view
Price target (mean) 26.43 +459.9% upside
Now 4.72
- Target (low)
- 20.00
- Target (mean)
- 26.43
- Target (high)
- 29.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.664 | -0.69 – -0.62 | -0.28 | -137.1% | 12.92M | -69.1% | 5 |
| Next quarter | -0.72 | -0.86 – -0.54 | 0.68 | -205.9% | 11.95M | -79.8% | 5 |
| Current year | 1.07 | 0.91 – 1.26 | -0.20 | +637.0% | 186.51M | +44.6% | 5 |
| Next year | -3.02 | -3.74 – -2.17 | 1.07 | -381.0% | 46.74M | -74.9% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | Initiated | — | Buy |
| Nov 6, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 6, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 26, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Aug 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 25, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 18, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 5, 2024 | Oppenheimer | Initiated | — | Outperform |
| Nov 27, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 22, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 9, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 2, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 24, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 3, 2023 | HC Wainwright & Co. | Initiated | — | Buy |
| Nov 8, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Aug 16, 2022 | Goldman Sachs | Maintained | — | Neutral |
| May 24, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Nov 24, 2021 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 23, 2021 | Cowen & Co. | Initiated | — | Outperform |
| Nov 23, 2021 | Goldman Sachs | Initiated | — | Neutral |